Ana L. Mazzeti

Passos, MG 37900106, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Development and Characterization of Innovative Nifurtimox Formulations as Therapeutic Alternative for Chagas Disease.

Development and Characterization of Innovative Nifurtimox Formulations as Therapeutic Alternative for Chagas Disease.

Journal: Tropical medicine and infectious disease

Published: December 26, 2024

Drugs in preclinical and early clinical development for the treatment of Chagas´s disease: the current status.

Drugs in preclinical and early clinical development for the treatment of Chagas´s disease: the current status.

Journal: Expert opinion on investigational drugs

Published: April 30, 2024

Profile of interstitial cells of Cajal in a murine model of chagasic megacolon.

Profile of interstitial cells of Cajal in a murine model of chagasic megacolon.

Journal: Anais da Academia Brasileira de Ciencias

Published: December 14, 2023

Trypanosoma cruzi antigen detection in blood to assess treatment efficacy and cure in mice models of Chagas disease.

Trypanosoma cruzi antigen detection in blood to assess treatment efficacy and cure in mice models of Chagas disease.

Journal: Frontiers in immunology

Published: November 18, 2023

Poly-ε-Caprolactone Implants for Benznidazole Prolonged Release: An Alternative to Chagas Disease Oral Treatment.

Poly-ε-Caprolactone Implants for Benznidazole Prolonged Release: An Alternative to Chagas Disease Oral Treatment.

Journal: Pharmaceutics

Published: December 21, 2022

The entrance route: Oral, mucous, cutaneous, or systemic has a marked influence on the outcome of Trypanosoma cruzi experimental infection.

The entrance route: Oral, mucous, cutaneous, or systemic has a marked influence on the outcome of Trypanosoma cruzi experimental infection.

Journal: Acta tropica

Published: March 29, 2022

The Impact of the CTHRSSVVC Peptide Upon Experimental Models of Trypanosoma cruzi Infection.

The Impact of the CTHRSSVVC Peptide Upon Experimental Models of Trypanosoma cruzi Infection.

Journal: Frontiers in cellular and infection microbiology

Published: February 23, 2022

N6-modification of 7-Deazapurine nucleoside analogues as Anti-Trypanosoma cruzi and anti-Leishmania agents: Structure-activity relationship exploration and In vivo evaluation.

N6-modification of 7-Deazapurine nucleoside analogues as Anti-Trypanosoma cruzi and anti-Leishmania agents: Structure-activity relationship exploration and In vivo evaluation.

Journal: European journal of medicinal chemistry

Published: November 22, 2021

4-nitrobenzoylcoumarin potentiates the antiparasitic, anti-inflammatory and cardioprotective effects of benznidazole in a murine model of acute Trypanosoma cruzi infection.

4-nitrobenzoylcoumarin potentiates the antiparasitic, anti-inflammatory and cardioprotective effects of benznidazole in a murine model of acute Trypanosoma cruzi infection.

Journal: Acta tropica

Published: November 10, 2021

7-Aryl-7-deazapurine 3'-deoxyribonucleoside derivative as a novel lead for Chagas' disease therapy: in vitro and in vivo pharmacology.

7-Aryl-7-deazapurine 3'-deoxyribonucleoside derivative as a novel lead for Chagas' disease therapy: in vitro and in vivo pharmacology.

Journal: JAC-antimicrobial resistance

Published: August 17, 2021

Combination therapy using nitro compounds improves the efficacy of experimental Chagas disease treatment.

Combination therapy using nitro compounds improves the efficacy of experimental Chagas disease treatment.

Journal: Parasitology

Published: July 12, 2021

A Potential Role of Cholinergic Dysfunction on Impaired Colon Motility in Experimental Intestinal Chagas Disease.

A Potential Role of Cholinergic Dysfunction on Impaired Colon Motility in Experimental Intestinal Chagas Disease.

Journal: Journal of neurogastroenterology and motility

Published: April 08, 2021

Showing 1-12 of 28

Last Updated: 09/26/2026